1. Is Marksans Pharma Ltd a good quality company?
Past 10 year's financial track record analysis by Moneyworks4me indicates that Marksans Pharma Ltd is a average quality company.
2. Is Marksans Pharma Ltd undervalued or overvalued?
The key valuation ratios of Marksans Pharma Ltd's currently when compared to its past seem to suggest it is in the Fair zone.
3. Is Marksans Pharma Ltd a good buy now?
The Price Trend analysis by MoneyWorks4Me indicates it is Semi Strong which suggest that the price of Marksans Pharma Ltd is likely to Rise-somewhat in the short term. However, please check the rating on Quality and Valuation before investing.
Data adjusted to bonus, split, extra-ordinary income, rights issue and change in financial year end.
Value Creation ⓘ
Value Creation Index Colour Code Guide ⓘ
|ROCE % ⓘ||77.5%||27.9%||21.1%||16.7%||1.5%||2.6%||8.7%||8.2%||18.6%||13.3%||-|
|Value Creation Index ⓘ||4.5||1.0||0.5||0.2||-0.9||-0.8||-0.4||-0.4||0.3||-0.1||-|
Growth Parameters ⓘ
Growth Parameters Colour Code Guide ⓘ
|YoY Gr. Rt. %||-||63.8%||28.8%||-11.7%||-39.7%||36.5%||44%||2.2%||38.3%||9.8%||-|
|Adj EPS ⓘ||1||1.4||1.5||1.7||0.1||0.2||1||0.9||2.4||2.2||2.7|
|YoY Gr. Rt. %||-||42.1%||8.9%||13.6%||-94%||80%||450%||-6.1%||160.2%||-9.5%||-|
|BVPS (₹) ⓘ||2.5||3.8||8.5||10||10.2||10.5||11.5||12.4||14.7||16.9||19.9|
|Adj Net Profit ⓘ||36.6||52||60.3||68.3||3.9||7.3||40.7||37.9||99.1||89.5||107|
|Cash Flow from Ops. ⓘ||8.6||54.2||112||64.8||-13.6||15.6||19.8||108||107||51||-|
|Debt/CF from Ops. ⓘ||10.6||1.7||0.5||0.6||-5.4||4.3||3.9||0||0||0.1||-|
CAGR Colour Code Guide ⓘ
|9 Years||5 Years||3 Years||1 Years|
|Adj EPS ⓘ||9.7%||85.4%||30.3%||-9.5%|
Key Financial Parameters ⓘ
Performance Ratio Colour Code Guide ⓘ
|Return on Equity % ⓘ||-93.6||38.5||23.3||17.5||0.9||1.7||9||7.8||17.9||12.9||14.4|
|Op. Profit Mgn % ⓘ||21.2||25||26.1||27.8||6.3||9.9||14.9||16.5||19.1||17.3||14.9|
|Net Profit Mgn % ⓘ||19||16.5||14.9||19.1||1.8||2.5||9.6||8.8||16.5||13.6||15.9|
|Debt to Equity ⓘ||0.8||0.6||0.1||0.1||0.2||0.2||0.2||0||0||0||0|
|Working Cap Days ⓘ||279||219||185||206||352||277||221||226||165||187||313|
|Cash Conv. Cycle ⓘ||164||126||102||127||260||208||166||157||105||122||218|
Return on Equity has increased versus last 3 years average to 14.40%
Sales growth is growing at healthy rate in last 3 years 15.78%
Net Profit is growing at healthy rate in last 3 years 30.30%
Sales growth is not so good in last 4 quarters at 8.89%
|TTM EPS (₹)||2.7||4.9|
|TTM Sales (₹ Cr.)||672||1,667|
|BVPS (₹.) ⓘ||19.9||31.3|
|Reserves (₹ Cr.) ⓘ||762||1,223|
|From the Market|
|52 Week Low / High (₹)||38.70 / 64.90|
|All Time Low / High (₹)||0.70 / 115.00|
|Market Cap (₹ Cr.)||2,571|
|Equity (₹ Cr.)||40.3|
|Face Value (₹)||1|
|Industry PE ⓘ||37.5|
Marksans Pharma, incorporated in 1992, was a wholly-owned subsidiary of Glenmark Pharmaceuticals. It became a separate entity in March 2003 and the name was changed to Marksans Pharma in 2005.
Currently the company has presence in Active Pharmaceuticals Ingredients (APIs), formulations and biopharmaceuticals. It is also actively engaged in research and development and offers contract research and manufacturing services (CRAMS) to global pharmaceutical companies.
The company, engaged in production of prescription drugs, caters in areas like oncology, gastroenterology, antidiabetic, cardiovascular, pain management, gynaecology and others.
The company's plants have been built as per USFDA guidelines and have received approval from various health authorities namely TGA (
Marksans Pharma acquired Relonchem, a leading
Marksans Pharma exports its products to markets in Europe, Latin America, Africa and
In 2010 Company entered into a Business Transfer Agreement with Kores (India) Limited
Research and Development- The companyâ€™s R&D centre is situated in
Formulation- This division is engaged in manufacturing of tablets, non-sterile liquids, ointments and powder products. The company owns one of the biggest manufacturing facility for soft gelatin in
APIs- Marksans' two APIs manufacturing units are located in Pune. The present manufacturing capacity of 1140 TPA that comprises of 600 TPA Quinolones, 360 TPA Ranitidine, and 180 others.
CRAMS- The company has alliances with the top 8 MNC generic companies for contract manufacturing of 30 generic products for the European markets. It has entered into licensing agreements with numerous companies for development and supply of products for 7-10 years.
2009 - Marksans Pharma establlished itself as a global player
2008 - Acquired Bells, Sons & Co. (Druggists) Ltd.
Acquired Relonchem Limited
2005 - Acquired Nova Pharmaceuticals Australasia Pty Ltd.
2003 - Spun-off into a separate entity - Glenmark Laboratories Ltd.
Changed its name to "Marksans Pharma Ltd"
2001 - Marksans was incorporated as a wholly owned subsidiary of Glenmark Pharmaceuticals Ltd.